Schafer, Peter

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia

Protein Degradation and InhibitorsMultiple Myeloma Research and Treatments

Cited by 814

Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate Tcells by inducing degradation of Tcell repressors Ikaros and Aiolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN

Gandhi, A. K., Kang, J., Havens, C. G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M. F., Thakurta, A., et al. (2014) · British Journal of Haematology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 619

A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos

Matyskiela, M. E., Zhang, W., Man, H.-W., Muller, G., Khambatta, G., Baculi, F., Hickman, M., LeBrun, L., Pagarigan, B., Carmel, G., et al. (2018) · Journal of Medicinal Chemistry

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 309

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Hagner, P. R., Man, H.-W., Fontanillo, C., Wang, M., Couto, S., Breider, M., Bjorklund, C., Havens, C. G., Lu, G., Rychak, E., et al. (2015) · Blood

Protein Degradation and InhibitorsLymphoma Diagnosis and Treatment

Cited by 203

Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration

Hoffmann, M., Kasserra, C., Reyes, J., Schafer, P., Kosek, J., Capone, L., Parton, A., Kim-Kang, H., Surapaneni, S., & Kumar, G. (2013) · Cancer Chemotherapy and Pharmacology

Pharmacogenetics and Drug MetabolismProtein Degradation and Inhibitors

Cited by 121

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

Gandhi, A. K., Mendy, D., Waldman, M., Chen, G., Rychak, E., Miller, K., Gaidarova, S., Ren, Y., Wang, M., Breider, M., et al. (2014) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 106

Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus

Schafer, P. H., Ye, Y., Wu, L., Kosek, J., Ringheim, G., Yang, Z., Liu, L., Thomas, M., Palmisano, M., & Chopra, R. (2018) · Annals of the Rheumatic Diseases

Systemic Lupus Erythematosus ResearchProtein Degradation and Inhibitors

Cited by 78

Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy

Thakurta, A., Gandhi, A. K., Waldman, M. F., Bjorklund, C., Ning, Y., Mendy, D., Schafer, P., Lopez-Girona, A., Lentzsch, S., Schey, S. A., et al. (2014) · Leukemia

Protein Degradation and InhibitorsMultiple Myeloma Research and Treatments

Cited by 56

Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis

Vidula, M. K., Orlenko, A., Zhao, L., Salvador, L., Small, A. M., Horton, E., Cohen, J. B., Adusumalli, S., Denduluri, S., Kobayashi, T., et al. (2021) · European Journal of Heart Failure

Cardiac Valve Diseases and TreatmentsAortic Disease and Treatment Approaches

Cited by 38

Development of a multi-biomarker risk score based on serum proteins by the Prognostic Lung Fibrosis Consortium (PROLIFIC)

Schafer, P., Rassa, J., Seyda, A., Hersey, S., Eisinger, D., Melin, J., Bencher, R., Neighbors, M., Mouded, M., Turner, S., et al. (2024) · Idiopathic interstitial pneumonias

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 0